Protocols

BlueRock expands Toronto ops; Unity brings B round to $151M; Novartis backs Altimmune’s $15M raise

⇨ Late last year Bayer and Versant Ventures turned some heads with a $225 million launch for a new stem cell player called BlueRock. Today, the startup announced that it had recruited industry vet Michael Scott as development chief as it created an R&D and manufacturing site in Toronto’s MaRS Discovery District. The biotech is collaborating with the Toronto-based McEwen Centre for Regenerative Medicine at University Health Network.

⇨ San Francisco-based Unity Therapeutics has added $35 million to its B round, bringing the total to a whopping $151 million. That money will be used to accelerate a move into the clinic with anti-aging remedies that focus on cellular senescence. The Arch startup added these new investors: INVUS Opportunities, Three Lakes Partners, Cycad Group, COM Investments, and Pivotal Alpha Limited. They joined Baillie Gifford, Fidelity Management and Research Company, Partner Fund Management, and Venrock. Other investors include Bezos Expeditions, Vulcan Capital, Founders Fund, WuXi PharmaTech, and Mayo Clinic Ventures.

Novartis US, HealthCap and Truffle Capital stepped in to help Gaithersburg, MD-based Altimmune $ALT raise $14.7 million.

⇨ Israel’s Intec Pharma $NTEC has raised $50 million through the sale of 10.6 million shares.

⇨ Houston-based Alzeca Biosciences has raised an $11 million A round for its work on novel MRI-based targeted imaging agents for the early diagnosis of Alzheimer’s disease and other neurodegenerative disorders.


The best place to read Endpoints News? In your inbox.

Full-text daily reports for those who discover, develop, and market drugs. Join 21,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biomanufacturing